Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
$44.99-1.60%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-29
Research Workspace
Put LQDA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Full year 2026 revenue: Comparison needs review.
View ThesisMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 72% in its worst 12-month stretch.
View RiskLQDA’s case rests on YUTREPIA sales growth and improving cash from operations, despite elevated risk. Recent financial performance is strong, though revenue was flat year over year in Q2 FY2026. That quarter beat on GAAP earnings, reporting $0.74 per share against $0.70 consensus. LQDA trades at 10× sales versus a 2× peer median and 21× its own historical multiple. The price reflects less growth than our forecast. A next-quarter miss probability near 45% threatens the case, and full-year 2026 revenue comparisons need review. Peer multiples imply a price about 19% below where it trades (it looks expensive on this basis); the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. LQDA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering LQDA (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for LQDA in the last 4 months.
Continue this research
Compare LQDA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LQDA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put LQDA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase YUTREPIA sales
Settlement boosts investor confidence and sales potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $44.99
The last 12 months of price, then the range of analyst 12-month targets from today’s $44.99.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase YUTREPIA sales
Upgrade suggests increased confidence in YUTREPIA sales growth.
Threatens: Achieve and sustain profitability
Settlement costs may hinder profitability objectives.
Advances: Improve cash from operations
Stock surge indicates improved market confidence and cash flow.
Settlement removes legal uncertainties, supporting profitability and growth.
Threatens: Advance clinical development of L606
Patent ruling concerns may hinder L606 clinical development.
Threatens: Achieve and sustain profitability
Court ruling negatively impacts profitability outlook.
Advances: Increase YUTREPIA sales
Yutrepia sales growth exceeds expectations.
